Thermo Fisher Acquires Rights to Preeclampsia Biomarker from Nephromics
May 17, 2012
Thermo Fisher Acquires Rights to Preeclampsia Biomarker from Nephromics
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
May 17, 2012 / ProteoMonitor - AmberGen Secures $600K to Develop Allergy Test on Illumina's BeadXpress Platform
May 15, 2012 / BioArray News - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor - Class Action Lawsuit Seeks to Stop Thermo Fisher's $13.6B Buy of Life Tech
April 23, 2013 / GenomeWeb Daily News - Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test
April 12, 2013 / ProteoMonitor